A guanidine-appended scyllo-inositol derivative AAD-66 enhances brain delivery and ameliorates Alzheimer's phenotypes.

Sci Rep · 2017 · PMC5658413 · PMID 29074878

Europe PMC DOI

hedged sentence

0.0692

closest p · 1.4× alpha

0.0692

boldest claim

The sentences

a decreasing trendp = 0.0692so close (0.05 < p ≤ 0.1)

The soluble Aβ42 levels in both AAD-66 and SI treated groups compared with the vehicle treated group showed a decreasing trend (p = 0.0692, p = 0.2451, respectively) (Fig. 3E ).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.